Equities research analysts expect Tandem Diabetes Care Inc (NASDAQ:TNDM) to announce earnings of ($0.23) per share for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Tandem Diabetes Care’s earnings. The lowest EPS estimate is ($0.42) and the highest is ($0.15). Tandem Diabetes Care posted earnings of ($0.34) per share during the same quarter last year, which would indicate a positive year over year growth rate of 32.4%. The company is scheduled to issue its next quarterly earnings report on Monday, July 29th.
On average, analysts expect that Tandem Diabetes Care will report full-year earnings of ($0.81) per share for the current fiscal year, with EPS estimates ranging from ($1.42) to ($0.33). For the next year, analysts forecast that the business will report earnings of ($0.28) per share, with EPS estimates ranging from ($0.59) to $0.37. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Tandem Diabetes Care.
Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Tuesday, April 30th. The medical device company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.10). Tandem Diabetes Care had a negative net margin of 50.73% and a negative return on equity of 40.76%. The business had revenue of $66.00 million for the quarter, compared to analysts’ expectations of $47.55 million. During the same quarter in the previous year, the firm earned ($1.82) EPS. Tandem Diabetes Care’s revenue was up 141.9% compared to the same quarter last year.
TNDM traded up $0.66 during trading hours on Tuesday, reaching $64.62. 932,810 shares of the company’s stock traded hands, compared to its average volume of 982,592. The company’s 50-day moving average price is $65.80. Tandem Diabetes Care has a 52-week low of $24.03 and a 52-week high of $74.81. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.43 and a quick ratio of 2.13. The firm has a market capitalization of $3.75 billion, a price-to-earnings ratio of -25.34 and a beta of 0.41.
In other Tandem Diabetes Care news, Director Dick Allen sold 17,000 shares of Tandem Diabetes Care stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $61.34, for a total transaction of $1,042,780.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David B. Berger sold 2,000 shares of Tandem Diabetes Care stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $63.09, for a total value of $126,180.00. Following the sale, the executive vice president now directly owns 3,765 shares of the company’s stock, valued at $237,533.85. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 105,066 shares of company stock valued at $7,136,287. 6.90% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of TNDM. Nisa Investment Advisors LLC raised its position in shares of Tandem Diabetes Care by 53.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 460 shares of the medical device company’s stock worth $30,000 after acquiring an additional 160 shares in the last quarter. Bremer Bank National Association bought a new position in shares of Tandem Diabetes Care in the 1st quarter worth $31,000. PNC Financial Services Group Inc. bought a new position in shares of Tandem Diabetes Care in the 4th quarter worth $44,000. Advisor Group Inc. raised its position in shares of Tandem Diabetes Care by 38.2% in the 4th quarter. Advisor Group Inc. now owns 2,351 shares of the medical device company’s stock worth $89,000 after acquiring an additional 650 shares in the last quarter. Finally, Rockefeller Capital Management L.P. bought a new position in shares of Tandem Diabetes Care in the 1st quarter worth $122,000. 80.44% of the stock is owned by institutional investors and hedge funds.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Featured Article: Liquidity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.